Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
4D Molecular Therapeutics
4D Molecular Therapeutics has announced several key personnel appointments, including Robert Fishman to the role of chief medical officer and therapeutic area head of pulmonology, Raphael Schiffmann to senior vice president and therapeutic area head of cardiology, and Robert Kim to senior vice president and clinical therapeutic area head of ophthalmology. Previously, Fishman served as chief medical officer at Xoc Pharmaceuticals, Schiffmann served as director of the Institute of Metabolic Disease at the Baylor Research Institute and Kim served as chief medical officer at Viewpoint Therapeutics.
Actinium Pharmaceuticals has appointed Mary Mei Chen vice president of clinical development. Prior to joining Actinium, Chen was senior medical director of medical oncology at GlycoMimetics.
Adagene has appointed Hua Gong chief operating officer and head of precision medicine. Gong most recently held the position of senior director of the genomics biomarker department at Novartis Navigate Biopharma. Adagene has also named JC Xu as chief scientific officer and Qinghai Zhao as chief manufacturing officer. Xu most recently served as head of China strategy for research and early development at Celgene, and Zhao was vice president of technical development and manufacturing at Forty Seven prior to joining Adagene.
David Clark has been named chief medical officer of Allena Pharmaceuticals. In his most recent role, Clark was chief medical officer of Aldeyra Therapeutics.
Gregory Mayes, former CEO of Engage Therapeutics, has been named CEO of Antios Therapeutics.
Apotex has appointed Peter Hardwick as the company’s new CEO. Previously, Hardwick was the company’s chief commercial officer.
Arena Pharmaceuticals has named Paul Streck as senior vice president of clinical development and chief medical officer. Streck most recently served as chief medical officer at Alder Biopharmaceuticals.
Cosmo Pharmaceuticals has found its newest chief medical officer in H. Jurgen Lenz, a gastroenterologist who currently serves as chief of the division of gastroenterology at Scripps Memorial Hospital.
Alex Lugovskoy has joined Dragonfly Therapeutics in the role of chief operating officer. Prior to this appointment, Lugovskoy was chief development officer of Morphic Therapeutic.
Elevar Therapeutics has hired Gus Aromin to take on the role of vice president of regulatory affairs. Aromin most recently served as senior director of regulatory affairs at Avanir Pharmaceuticals.
Spiros Jamas, founding CEO of AoBiome, has been appointed CEO of Entera Bio.
FibroGen has appointed Mark Eisner chief medical officer of the company. Eisner previously served as senior vice president and global head of product development immunology, infectious disease and ophthalmology at Genentech.
Faheem Haisnan is set to rejoin Gossamer Bio as CEO just two years after he left the company. Haisnan was previously the CEO of Receptos and currently serves on the board of Aspen Neuroscience.
Laura Niklason, founder of Humacyte, has been appointed president and CEO of the company. Niklason was most recently vice chair of anesthesiology at Yale University.
Jim Meyers, a former executive vice president and chief commercial officer at Gilead Sciences, has been appointed president and CEO of IntraBio.
Glenn Crater has been appointed chief medical officer of Inversago Pharma. Most recently, Crater was vice president of respiratory portfolio at Theravance Biopharma.
Suba Krishnan has been named senior vice president of clinical development of Mereo BioPharma. Most recently, Krishnan was the global program head of immuno-oncology at Genmab.
Mersana Therapeutics has named Arvin Yang senior vice president and chief medical officer. Prior to joining Mersana, Yang was vice president and head of clinical hematology at Bristol Myers Squibb.
Curt Bradshaw has been appointed chief scientific officer of NeuBase Therapeutics. Bradshaw’s most recent role was as chief scientific officer at Arrowhead Pharmaceuticals.
Ilan Hadar has been chosen to lead PainReform as the company’s newest CEO. Most recently, Hadar was the country manager Israel and chief financial officer at Foamix Pharmaceuticals.
Penrose TherapeuTx has found its newest CEO in Mark de Souza, former CEO of Revolution Global.
PureIMS has named Bram van Dijck as its new CEO. Van Dijck most recently served as global head portfolio management at the Grünenthal Group.
Joel Moody has joined Revive Therapeutics to assist the company in expanding its clinical studies in Canada. Moody previously served as a medical and clinical adviser for clinical trials, including research in oncology and infectious disease.
Darrin Beaupre has been hired as Samumed’s new chief medical officer of oncology. Most recently, Beaupre was a senior vice president of Pfizer.
Mahkam Zanganeh, former CEO of Maky Zanganeh and Associates, has been appointed chief operating officer of Summit Therapeutics.
Tarus Therapeutics has brought on Brian Schwartz as acting chief medical officer. Schwartz previously served as chief medical officer for arQule.
Matt Walz has taken the helm of Trialbee as its new CEO. Most recently, Walz was the general manager of life sciences at Aurea Software. Trialbee also recently named Lollo Eriksson as the company’s chief strategy officer. Eriksson has served as the company’s CEO over the past three years.
Emerging biotechnology company TYME Technologies has announced the appointment of Richie Cunningham to CEO. Cunningham was most recently president and CEO of Icagen.
Venatorx Pharmaceuticals has named Robert Waltermire as senior vice president of chemistry, manufacturing and controls. Waltermire joins Venatorx from Palatin Technologies, where he served as senior vice president of product development.
Louis Montiy has been appointed vice president of translational medicine at VistaGen Therapeutics. Montiy previously served as president and CEO of Pherin Pharmaceuticals.
Jeffrey Hatfield has been named CEO of Vividion Therapeutics. Hatfield was formerly the CEO of Vitae Pharmaceuticals.
Ryan Sullivan has been appointed head of Wugen’s natural killer-cell research targeting its leukemias and lymphomas program. Sullivan joins Wugen from the Novartis Institutes for Biomedical Research, where he was a principal scientist and investigator.
Alan Sandler has been named president and head of global development for oncology at Zai Lab. Previously, Sandler served as vice president and global head of lung and head/neck cancer franchise at Genentech.